Trial Profile

HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms SABES

12 Jul 2021 Status changed from active, no longer recruiting to completed.
10 Mar 2021 Paired blood samples of 6 HIV-infected individuals from this study were used to assess C Y Tokine Dysregulation and Antigen Responses Drive T-Cell Expansion in Hiv Infection presented at the 28th Conference on Retroviruses and Opportunistic Infections
10 Mar 2021 Results (n=50 (21 of Immediate ART and 29 of deferred ART ) assessing effect of Hiv acquisition on systemic inflammation in a seroconversion cohort, presented at the 28th Conference on Retroviruses and Opportunistic Infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com